VANCOUVER, Sept. 3 /CNW/ - Protox Therapeutics Inc. (TSX:PRX), a leader in the development of receptor targeted fusion proteins, announced today that it has completed enrollment of patients for its Phase 2 study of PRX302 in males with moderate to severe benign prostatic hyperplasia (BPH), a common and bothersome urological condition that affects more than 1 million men in Canada and over 50 million men worldwide.
